CIVABRADINE ivabradine (as hydrochloride) 7.5 mg tablet blister pack

País: Australia

Idioma: inglés

Fuente: Department of Health (Therapeutic Goods Administration)

Ingredientes activos:

ivabradine hydrochloride, Quantity: 8.085 mg (Equivalent: ivabradine, Qty 7.5 mg)

Disponible desde:

Arrotex Pharmaceuticals Pty Ltd

formulario farmacéutico:

Tablet, film coated

Composición:

Excipient Ingredients: magnesium stearate; lactose monohydrate; colloidal anhydrous silica; maize starch; maltodextrin; titanium dioxide; hypromellose; iron oxide yellow; iron oxide red; macrogol 4000

Vía de administración:

Oral

Unidades en paquete:

14, 56

tipo de receta:

(S4) Prescription Only Medicine

indicaciones terapéuticas:

Treatment of chronic stable angina Symptomatic treatment of chronic stable angina due to atherosclerotic coronary artery disease in patients with normal sinus rhythm and heart rate at or above 70 bpm, who are unable to tolerate or have a contraindication to the use of beta-blockers.,Treatment of chronic heart failure Treatment of symptomatic chronic heart failure of NYHA Classes II or III and with documented left ventricular ejection fraction (LVEF) ? 35% in adult patients in sinus rhythm and with heart rate at or above 77 bpm, in combination with optimal standard chronic heart failure treatment.

Resumen del producto:

Visual Identification: Ivabradine 7.5 mg is light salmon, round (7 mm diameter), biconvex film-coated tablet.; Container Type: Blister Pack; Container Material: Al/Al; Container Life Time: 36 Months; Container Temperature: Store below 25 degrees Celsius

Estado de Autorización:

Registered

Fecha de autorización:

2018-01-11